New agents in gastrointestinal malignancies: Part 2: Gemcitabine in clinical practice

Cancer Nursing

Volumn 22, Issue 4, 1999, Pages 290-296

  Stucky Marshall, Lisa ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Clinical benefit response; Gemcitabine; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; IRINOTECAN;

ARTICLE; CLINICAL PRACTICE; COLON CANCER; DIGESTIVE SYSTEM CANCER; DRUG SAFETY; HUMAN; NURSE; PANCREAS CANCER; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0032771442     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002820-199908000-00005     Document Type: Article

References (19)

1. Lundis SH, Taylor M, Bolden S Wingo PA. Cancer statistics 1998. CA Cancer J Clin 1998;48:6-29.
2. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-53.
3. Wagener DJT, Verdonk HER, Dirix LL, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer: an EORTC early clinical trials group study. Ann Oncol 1995;6:129-32.
4. Lund B, Kristjansen PEG, Hansen HH. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 1993;9:45-55.
5. Kaye SB. Gemcitabine: current status of phase I and II trials. J Clin Oncol 1994;12:1527-31.
6. Stadler W, Kuzel T, Raghavan D, Levine E, Vogelzang N, Dorr FA. A phase II study of gemcitabine in the treatment of patients with advanced transitional cell carcinoma. Proc Am Soc Clin Oncol 1995;14. [abstract 638]
7. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110-17.
8. Ruiz Van Haperen VWT, Veerman G, Vermorken JB, Peters GJ. 2′,2′-difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 1993;46:762-6.
9. Hansen HH. Gemcitabine: preclinical and phase I studies. In: Hansen, HH, ed. Gemcitabine: a new approach to the management of solid tumours. Adelphi Mill, Bollington, U.K.: Adelphi Communications, 1995:5-8.
10. Plunkett W, Gandhi V, Chubb S, et al. 2′,2′-difluorodeoxycytidine metabolism and mechanism or action in human leukemia cells. Nucleosides Nucleotides 1989;8:775-85.
11. Heinemann V, Hertel LV, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024-31.
12. Physician's Desk Reference. GEMSAR brand of gemcitabine hydrochloride injection. In: Arky R, ed. Physician's desk reference. Montvale, New Jersey: Medical Economics Data Production Company, 1997:1482-5.
13. Rothenberg ML. Clinical benefit for the pancreas cancer patient. Satellite: new drugs for difficult cancers: a critical review. ESMO 21st Congress. Vienna: Adelphi, 1996:17-22.
14. Andersen JS, Burris HA, Casper E, et al. Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 1994;13. [abstract 1600]
15. Moore M, Andersen J, Burris H, et al. A randomized trial of gemcitabine (GEM) versus 5-FU as first-line therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol 1995:14. [abstract 473]
16. Shewach D, Lawrence T. Radiosensitization of human tumor cells by gemcitabine in vitro. Lilly Oncology Global Medical Conference. Adelphi Mill, Bollington, U.K.: Adelphi Communications, 1995:18-19.
17. Fosella F, Lippman S, Shin D, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 1997;15:310-16.
18. Sandler A. Nemunaitis J, Dehnam C, et al. Phase III study of cisplatin with or without gemcitabine in patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1998;17. [abstract 1747]
19. Crino' L, Conte P, DeMarinis F, et al. A randomized trial of gemcitabine cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a multicenter phase III study. Proc Am Soc Clin Oncol 1998;17. [abstract 1750]